SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): September 24, 2003
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
- -------- ------- ----------
(State or Other Jurisdiction (Commission File Number (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On September 24, 2003, the Registrant disseminated a Press Release
announcing the election of Athanase Lavidas, Ph.D., chairman and
chief executive officer of the Lavipharm Group, to its Board of
Directors.
The information contained in the Press Release dated September 24,
2003, is incorporated herein by reference and attached as Exhibit
99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated September 24,
2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: September 24, 2003
2
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- -------------------------
99.1 The Registrant's Press Release dated 4
September 24, 2003.
3